Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 12/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | DDO | Q99489 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30482258 | 1.00 | BRD4 (0.42) | BRD4ATAD2DAODDOPARP1 | |
| SCHEMBL29266494 | 0.81 | DAO (0.41) | DAODDOPARP1 | |
| SCHEMBL30617953 | 0.81 | DAO (0.41) | DAODDOPARP1 | |
| SCHEMBL25604921 | 0.80 | DAO (0.38) | DAODDO | |
| SCHEMBL30235048 | 0.80 | DAO (0.38) | DAODDO | |
| SCHEMBL30617995 | 0.80 | PARP1 (0.44) | BRD4ATAD2DAODDOPARP1 | |
| SCHEMBL29266513 | 0.80 | PARP1 (0.44) | BRD4ATAD2DAODDOPARP1 | |
| SCHEMBL32673963 | 0.79 | KDM4E (0.34) | — | |
| SCHEMBL22199030 | 0.78 | NQO2 (0.43) | BRD4ATAD2 | |
| SCHEMBL25376520 | 0.76 | BRD4 (0.41) | BRD4ATAD2DAODDOPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12384780-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-120081844-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-118804916-B | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-04-01 | — | — | CN | disclosed |
| EP-4469449-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-4466269-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240368162-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118804916-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118510767-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11939329-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2024041643-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023146957-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146957-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023141290-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141290-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384780-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | BRD4 37/4885ATAD2 1007/4885DAO 4505/4885 |
| US-11939329-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | BRD4 37/4885ATAD2 1007/4885DAO 4505/4885 |
| US-20230234952-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | BRD4 37/4885ATAD2 1007/4885DAO 4505/4885 |
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP16 | BRD4 28/4885ATAD2 1674/4885DAO 2762/4885 |
| US-20240368162-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | BRD4 37/4885ATAD2 1007/4885DAO 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.